Introduction ▼
Optimal treatment of congenital adrenal hyperplasia, particularly in its most severe salt-wasting form (CAH-SW), with appropriate doses of glucocorticoids and mineralocorticoids should promote growth, puberty and fi nal height in a close to normal pattern. The disease may predispose for early puberty because children with the diagnosis of CAH and late initiation of corticosteroid treatment and / or poor compliance are at risk of developing secondary central (GnRHdependent) precocious puberty (CPP) with early maturation of the hypothalamic-pituitarygonadal axis ( Soliman et al., 1997 , Partsch and Sippell, 2001 ). The precocious initiation of puberty causes acceleration of growth, bone age advancement and secondary sexual characteris-Treatment of congenital adrenal hyperplasia (CAH) in its salt-wasting form with appropriate doses of glucocorticoids and mineralocorticoids should promote growth, puberty and fi nal height in a similar to normal pattern. However, the individual requirements for these drugs to normalize the hormonal profi le and to achieve a physiologic growth pattern may diff er. Moreover, the time of onset of puberty is also unpredictable since the course of the disease may predispose for precocity. The aim of this study was to explain the unexpected arrest of growth during puberty in a boy with late-onset CAH, who had been treated with glucocorticoid from early childhood. A short course of GnRH agonist treatment was also introduced in later years. The growth chart refl ects two periods of impaired growth velocity preceded by weight loss. The reason for the fi rst decline is diffi cult to prove retrospectively, but during the second episode the boy became both clinically and hormonally hypogonadal. At that time the anorexia nervosa (AN) was diagnosed according to APA DSM-IV criteria. We conclude that there were several reasons for the discontinued growth spurt and reduced fi nal height in this boy with CAH: (a) early variant of puberty and subsequent late treatment with GnRH agonist, (b) AN possibly occurring during mid-childhood and clearly during puberty and (c) the repeated use of high doses of glucocorticoids. AN, a relatively rare disorder in boys, appears to have had a signifi cant negative eff ect on this patient ' s growth and should be considered in the diff erential diagnosis in CAH children with impaired growth. 
Patient Report ▼
A male patient with late-onset CAH was studied in whom the 21-hydroxylase defi ciency was detected by serum hormone analysis and urine steroid profi le during early childhood. After diagnosis at 4 years (growth acceleration, precocious pubarche and penile enlargement), the patient was treated with hydrocortisone (later with prednisone) and fl udrocortisone (Cortineff ). He also received short-term treatment with GnRHa (between years 11.5 and 12.8) and with 0.25 mg dexamethasone (at bedtime) combined with morning doses of hydrocortisone and fl udrocortisone between years 13.0 and 14.8. The auxological data plotted on a growth chart ( Krawczynski et al., 2000 ) were combined with the available hormonal data and bone age ( • ▶ Fig. 1 ). At 12.5 years bone age, originally advanced, was fortunately the same as chronological age at which was a very promising fi nding in view of his predicted adult height (PAH) close to 178 cm compared to his target height (TH) of 177 cm. PAH was calculated according to Bayley and Pinneau 1952 , based on height and corresponding bone age (BA). At the age of 5.3 years, PAH was calculated to be 166 cm, at 9 to be 178 cm, at 11 years to be 176 cm and at 15.3 years it was still 170 cm. Longterm analysis of his growth chart revealed 2 periods of impaired growth velocity, the fi rst between 9 and 11 years and the second, with an arrest of growth, between 15.3 yrs (BA 14.75) and 17.8 years of age, when his height was 162 cm ( • ▶ Fig. 1 , Table 1 ). A a concomitant weight loss was observed in both periods. The reason for the fi rst decline in growth, possibly due to AN, is diffi cult to prove retrospectively but it appears not to be as relevant for his PAH as the second drop. During the second episode, the clinical and hormonal features of hypogonadism were observed with a dramatic decline in testosterone levels (from 20.6 nmol / L to 4.0 nmol / L) and an accompanying decrease of LH from 7.0 (evaluated after withdrawal of GnRHa) to 1.8 mIU / mL and of FSH from 33.3 (evaluated after withdrawal of GnRHa) to 8.7 mIU / mL. Serum GH levels were normal in two tests (spontaneous nocturnal secretion and after clonidine-stimulation test). IGF-1 level at the time of arrested growth was below the mean for age and sex, close to -1 SD (IGF-I normogram developed by DSL, Inc., Texas, USA, http: / / www.dslabs.com / , 2005). MRI of the head and thyroid were normal. Based on the patient ' s history and clinical state of (a) an intense fear of becoming fat or gaining weight, (b) a refusal to maintain body weight at or above a minimal normal weight for age and height, (c) a disturbed body image, undue infl uence of shape or weight on self-evaluation, AN was diagnosed according to American Psychiatric Association DSM-IV criteria (1994). This boy did not grow at all for 2 years and 6 months (from 15.3 -17.8 years of age). His weight returned to the previous value during a clinical course with testosterone (100 mg / 4 weeks for 8 months) followed by a height gain of 2 cm. The testosterone treatment was stopped when his gonadotropin values reached pubertal levels (LH 2.5 mIU / mL and FSH 6.7 mIU / mL,) and his serum testosterone level was pubertal (14.0 nmol / L) before the next testosterone injection, showing recovery of the hypothalamic-pituitary-gonadal axis. He completed growth at a fi nal height of 164 cm (height SDS for BA = − 1.9, height percentile for BA: -3, height SDS -target height SDS = − 1.7). In retrospect it seems very likely that the fi rst episode of weight loss was also a manifestation of early-onset AN in a prepubertal boy.
Discussion ▼
Although AN is usually considered a disorder of girls and young women, 5 -10 % of cases occur in boys ( Sreenivasan, 1978 , Romeo, 1994 and adult men ( Andersen and Holman, 1997 ). Time of onset of AN can range from the prepubertal years to adulthood ( Fosson et al., 1987 , Barry and Lippmann, 1990 ) . The AN patients in the study by Nussbaum et al. 1985 were signifi cantly shorter than their parents, and comparisons suggest impairment of growth rather than familial etiology. In those subjects who developed AN after menarche, malnutrition did not appear to be responsible for height defi cits. AN is therefore not causative in ending the growth phase. Nutritional status must be regarded as a major determinant in the regulation of the somatotropinsomatomedin axis in animals and humans. Chronic undernutrition induces an increase in spontaneous GH secretion with a decrease in insulin-like growth factor-1 plasma levels ( Scacchi et al., 2003 ) . CAH is not a disorder with an increased risk of developing AN ( Robb and Dadson, 2002 ) . To date no data are available describing this problem in boys with CAH and there is only one paper describing AN in girls with this condition ( Brand et al., 2000 ) . AN is improbable in a boy with CAH since in this disease the problem of androgen excess rather than defi ciency occurs, the latter a known important secondary parameter in AN boys. There is no adequate data supporting the association of CAH and AN in terms of the primary reason, e. g. whether longterm treatment of chronic disease with hydrocortisone had any relevant eff ect on psychological behaviour resulting in AN crisis. Anorectic patients have signifi cantly reduced IGF-1 and IGFBP-3 and increased IGFBP-1 concentrations, and these values do not normalize even after recuperation of more than 10 % of body weight ( Barrios et al., 2001 ). Patients with AN may present with partial GH resistance, as suggested by reduced GHBP concentration ( Argente et al., 1997 ) . The anorectic male patient with lateonset CAH described here had reduced IGF-1 concentration at the time of diagnosis as well as normal or even elevated GH levels, thus supporting the above. Moreover, this happened during a critical period for growth spurt which results from the synergistic action of GH (via IGF-1) and testosterone. Both critical compounds, IGF-1 and testosterone, were decreased, therefore very probably causing arrested growth. It should be noted that treatment with GnRHa was not indicated retrospectively, at least in the period between 11 and 13 years, which is the physiological time for pubertal onset in boys and in view of the fact that his bone age was not signifi cantly advanced (12 years at a chronological age of 11. may result in decreased STAT5 activation and thus in reduced growth. This could provide a very convincing and novel explanation for growth disorders in later life due to an extended period of very low glucorticoid levels, below the age of 4 in this boy when this boy was not treated.
In conclusion, the main reason for arrested growth in the boy with late-onset CAH described here was the suppression of puberty, shown by a sharp decline in gonadotropins and testosterone secretion with a concomitant decrease of IGF-1 concentration into the prepubertal range. The reasons for the discontinued growth spurt and reduced fi nal height in this boy were multifactorial: (a) secondary early central puberty and subsequent treatment with GnRH agonist, (b) AN during puberty with a severe decline in sex hormone levels and (c) long-term treatment with periodically high doses of glucocorticoids. The diagnosis of AN, which is quite a rare disorder in boys, seems to be an important infl uencing factor and should be considered in children suff erring from CAH with impaired growth.
